// App-Quantinova.ai

3840 : Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Researchers

Presenter

  • Seiichi Okabe

Principal Investigators

  • Tetsuzo Tauchi

  • Yuko Tanaka

  • Seiichiro Katagiri

  • Toshihiko Kitahara

  • Kazuma Ohyashiki

Medical Centers

  • Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan

  • First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

  • Tokyo Medical University Hospital, Tokyo Medical University, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

Biomarkers

  • B-cell lymphoma 2

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • Ph chromosome

Drug/Treatment

  • Omacetaxine mepesuccinate

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved